Lineage Cell Therapeutics, Inc.
(NYSE Amex Equities : LCTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 4.22%207.600.0%$1757.24m
BIIBBiogen, Inc. -2.00%380.691.7%$1272.32m
SNSSSunesis Pharmaceuticals, Inc. -0.16%12.740.7%$890.57m
NVAXNovavax, Inc. 3.85%181.1279.8%$703.76m
AMGNAmgen, Inc. 0.52%239.931.3%$657.26m
BNTXBioNTech SE 5.80%224.740.0%$555.37m
VRTXVertex Pharmaceuticals, Inc. 0.06%187.971.9%$517.64m
GILDGilead Sciences, Inc. 1.08%67.331.0%$498.68m
REGNRegeneron Pharmaceuticals, Inc. -0.82%533.502.7%$381.65m
ILMNIllumina, Inc. 0.96%460.523.5%$368.65m
ALXNAlexion Pharmaceuticals, Inc. -0.06%180.592.0%$338.73m
OCGNOcugen, Inc. 12.02%7.360.0%$321.17m
EXASEXACT Sciences Corp. 0.48%127.1318.1%$189.98m
TXG10X Genomics, Inc. 1.58%197.510.0%$176.50m
TECHBio-Techne Corp. 1.77%439.544.5%$162.60m

Company Profile

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.